The news of Diane Ladd’s death at 89 has brought attention to a rare but serious lung condition. The legendary actress, known ...

The field of PPF is moving towards a personalized, data-driven approach, emphasizing biomarker integration and risk stratification for early diagnosis and treatment. Recent guidelines standardized PPF ...

CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the ...

SAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients ...

More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...

The investigators also reported that LTI-03 helped preserve alveolar epithelial type II (AT2) progenitor cells, which are essential for lung repair and regeneration. Current IPF therapies primarily ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with ...